Bicara Therapeutics Inc. Common Stock
BCAX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $506,669 | $709,568 | $948,345 |
| - Cash | $171,673 | $436,606 | $462,065 | $489,711 |
| + Debt | $880 | $2,238 | $591 | $738 |
| Enterprise Value | – | $72,301 | $248,094 | $459,372 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$36,234 | -$31,999 | -$41,769 | -$26,622 |
| % Margin | – | – | – | – |
| Net Income | -$36,330 | -$27,388 | -$36,846 | -$20,957 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.67 | -0.5 | -0.68 | -0.38 |
| % Growth | -34% | 26.5% | -78.9% | – |
| Operating Cash Flow | -$29,248 | -$25,594 | -$28,106 | -$30,032 |
| Capital Expenditures | -$42 | $0 | $0 | -$40 |
| Free Cash Flow | -$29,290 | -$25,594 | -$28,106 | -$30,072 |